Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms
The purpose of this study is to assess FOLFIRI+aflibercept efficacy in patients with or without ACE polymorphisms in terms of Progression-free survival (PFS).
Metastatic Colorectal Cancer
DRUG: FOLFIRI+aflibercept
FOLFIRI+aflibercept efficacy in terms of Progression-free survival (PFS) with or without ACE polymorphisms., 30 months
Progression free survival (PFS) with or without AGTR1 polymorphisms, according Serum-level sACE, 30 months|Objective Response Rate (ORR) with or without ACE polymorphisms, AGTR1 polymorphisms, according Serum-level sACE, 30 months|Disease Control Rate (DCR) with or without ACE polymorphisms, AGTR1 polymorphisms, according Serum-level sACE, 30 months|Time to progression (TP) with or without ACE polymorphisms, AGTR1 polymorphisms, according Serum-level sACE, 30 months|Time to treatment failure (TTF) with or without ACE polymorphisms, AGTR1 polymorphisms, according Serum-level sACE, 30 months|Overall survival (OS) with or without ACE polymorphisms, AGTR1 polymorphisms, according Serum-level sACE, 30 months|Number of participants with adverse events as assessed by CTCAE v4.0., 30 months
Plasma VEGF levels circulating and their correlation with tumour-efficacy parameters (ORR, PFS and OS), 30 months|Other biomarkers in serum and tumour tissue associated with cell and tumour growth and/or involved in the mechanism of action of FOLFIRI+aflibercept and their correlation with tumour-efficacy parameters (ORR, PFS and OS), 30 months
The purpose of this study is to assess FOLFIRI+aflibercept efficacy in patients with or without ACE polymorphisms in terms of Progression-free survival (PFS).